Delivery Order SPE2DR25D2006-SPE2DR26F57FM
Award Date 1/9/26
Potential Completion Date 1/12/26
Potential Value $64K
Federal Agency
Awardee
Ultimate Awardee
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a delivery order valued at $3,129.52 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on December 22, 2025, with an ultimate completion date of December 23, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and is being performed at the vendor's corporate office location in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for adult immunization,...
- The Defense Logistics Agency awarded a $61,478.90 delivery order to AmerisourceBergen Drug Corp on December 23, 2025, for the supply of HEPLISAV-B 20 MCG/0.5 ML syringes. This is a firm fixed-price, competitively awarded contract with an ultimate completion date of December 24, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting the company's competitive standing in the federal...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,992.40 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on June 2, 2025, with completion scheduled for June 3, 2025. This competitively awarded, firm fixed-price delivery order was issued without set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for adult immunization, representing part of...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes, valued at $10,347.75 under a firm fixed-price contract. This non-set-aside delivery order was awarded on December 2, 2025, with an ultimate completion date of December 3, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for adults aged 18 and older,...
- The Defense Logistics Agency awarded a delivery order valued at $114,722.94 to AmerisourceBergen Drug Corp for HEPLISAV-B vaccine (20 mcg/0.5 ml syringes). This competitively awarded, firm fixed-price delivery order was issued on September 3, 2025, with an ultimate completion date of September 4, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. No set-aside designation was applied to this award. This delivery order is issued under AmerisourceBergen Drug...
- The Defense Logistics Agency awarded a $2,447.64 delivery order to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on December 1, 2025, with completion scheduled for December 2, 2025. This is a firm fixed-price delivery order with no set-aside designation, meaning it was competitively awarded. The contract will be performed at AmerisourceBergen's Conshohocken, Pennsylvania location. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for adults 18 years and older, and...
- The Defense Logistics Agency awarded a delivery order valued at $21,291.00 to AmerisourceBergen Drug Corp for HEPLISAV-B, a hepatitis B vaccine supplied as a 20 microgram per 0.5 milliliter injection in pre-filled syringes. The contract is a firm fixed-price delivery order with an ultimate completion date of January 6, 2026, and was competitively awarded without a set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the delivery from its corporate...
- The Defense Logistics Agency awarded a delivery order valued at $3,298.76 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on October 24, 2025, with completion scheduled for October 27, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania location. The order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,129.05 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on January 5, 2026, with completion scheduled for January 6, 2026. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a single delivery transaction for the hepatitis B vaccine product. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $15,164.64 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on July 22, 2025, with an ultimate completion date of July 23, 2025. The contract utilizes firm fixed pricing with no set-aside designation, indicating competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical federal medical procurement vendor, particularly...